BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24188258)

  • 1. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
    Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
    Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary treatment of high-risk localized prostate cancer.
    Tareen B; Kimmel J; Huang WC
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1069-76. PubMed ID: 20645696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Place of surgery in high-risk tumours of the prostate].
    Soulié M; Rozet F; Hennequin C; Salomon L;
    Cancer Radiother; 2010 Oct; 14(6-7):493-9. PubMed ID: 20727805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
    Gomella LG; Zeltser I; Valicenti RK
    Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
    Roach M
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is there an indication for adjuvant or neoadjuvant systemic therapy in prostate cancer?].
    Börgermann C; Miller K; vom Dorp F; Jäger T; Rübben H
    Urologe A; 2007 Oct; 46(10):1385-6, 1388. PubMed ID: 17874231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
    Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
    Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
    Andriole GL
    Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
    Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.